Shortening hepatitis C treatment could become a decisive lever in the global effort to eliminate the virus, according to a commentary published in The Lancet. The analysis focuses on the two recommended first-line oral regimens that have reshaped clinical management since their approval and asks whether fewer weeks of therapy can widen access without sacrificing the high cure rates that made elimination conceivable in the first place.
The arrival of simple direct-acting antiviral treatment transformed hepatitis C virus care. The first pan-genotypic fixed-dose combination, sofosbuvir–velpatasvir, was approved in 2016. The second, glecaprevir–pibrentasvir, followed in 2017. Both are recommended as first-line therapy for people with or without compensated cirrhosis, and both share the features that made elimination a realistic public health goal: high efficacy, excellent tolerability, oral administration and once-daily dosing.
The regimens diverge in ways that matter for patients and health systems. Sofosbuvir–velpatasvir is taken as one tablet daily for 12 weeks and is available as a generic formulation. Glecaprevir–pibrentasvir is taken as three tablets daily for 8 weeks and remains under patent protection. The contrast sets up the central question of the commentary: whether a shorter course can deliver the same clinical results while reducing the burden on patients, providers and payers.
Treatment duration is not a minor logistical detail in hepatitis C. Every additional week of therapy represents more pills to supply, more opportunities for adherence to slip and more cost to whoever is paying. In settings where health budgets are stretched and the number of people needing treatment is large, the difference between eight and twelve weeks can shape how quickly programs move through their waiting lists. The commentary frames shortening treatment as a way to accelerate elimination rather than merely streamline individual care.
The two regimens also differ in pill burden and availability, factors that interact with duration. A once-daily single tablet is simpler for patients to manage, while a three-tablet daily regimen places a higher demand on adherence even over a shorter period. Generic availability of sofosbuvir–velpatasvir affects price and procurement, whereas patent protection on glecaprevir–pibrentasvir influences cost and supply. Those differences mean the choice between regimens is not only clinical but also economic and operational.
Both drugs carry the profile that made elimination plausible: they are highly effective, well tolerated and taken by mouth once a day. The commentary treats those shared strengths as the foundation on which shorter courses might be built, while acknowledging that the two options are not interchangeable in practical terms. Efficacy and tolerability are necessary but not sufficient; duration, pill count and availability determine whether a regimen can be deployed at the scale elimination requires.
The stakes are global. Hepatitis C elimination depends on treating large numbers of people efficiently, and any reduction in treatment length that preserves cure rates would ease pressure on clinics, drug budgets and patient schedules. The commentary positions shortened therapy as a practical route to that goal, one that could help health systems treat more people with the same resources. It does not present shortening as a substitute for the existing regimens but as a way to extend their reach.
For clinicians, the message is that regimen selection now involves weighing duration and pill burden alongside efficacy. For policymakers, the commentary points to treatment length as a variable that can be managed to speed progress toward elimination targets. The debate over eight weeks versus twelve weeks is, in that sense, a debate about how fast the world can finish the job it started when pan-genotypic oral therapy first became available a decade ago.
8
